Convexia

Executive Summary

Convexia is a preclinical-stage neuroscience biotech developing disease-modifying therapeutics for neurodegenerative and neuropsychiatric disorders. The company focuses on synaptic dysfunction and neuronal resilience pathways, leveraging advanced neurobiology insights to address high unmet medical needs. Its platform targets core mechanisms underlying conditions such as Alzheimer's, Parkinson's, and major depressive disorder, aiming to halt or reverse disease progression rather than just manage symptoms. Convexia is part of the Y Combinator biotech cohort, indicating early-stage validation and access to a strong network for growth. With a lean team of 1-50 employees, the company is capital-efficient and agile, though it lacks disclosed funding details and specific pipeline assets. As a private preclinical entity, Convexia faces significant technical and regulatory risks inherent to early-stage drug development. Success hinges on advancing lead candidates through preclinical proof-of-concept and into IND-enabling studies within the next 12–18 months. The company's novel approach to neuronal resilience differentiates it from competitors targeting amyloid or tau, but clinical validation remains years away. The conviction score reflects the high uncertainty of preclinical assets, tempered by the promising biology and Y Combinator support.

Upcoming Catalysts (preview)

• Q3 2026Lead Candidate Nomination for Neurodegenerative Program60% success
• Q1 2027Preclinical Proof-of-Concept Data in Animal Models50% success
• Q2 2027Initiation of IND-Enabling Toxicology Studies40% success